The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

2016120 citationsJournal Articlehybrid Open Access

Authors

Ivy Song · Research Triangle Park Foundation

Jian Zong · Research Triangle Park Foundation

Julie Borland · GlaxoSmithKline (United States)

Fred Jerva · Research Triangle Park Foundation

Brian Wynne

Maciej J. Zamek‐Gliszczynski · GlaxoSmithKline (United States)

Joan E. Humphreys · Research Triangle Park Foundation

Abstract

Dolutegravir significantly increased metformin plasma exposure, which can be partially explained by OCT2 inhibition. It is recommended that dose adjustments of metformin be considered to maintain optimal glycemic control when patients are starting/stopping dolutegravir while taking metformin.

Topics & Keywords

HIV/AIDS drug development and treatment Drug Transport and Resistance Mechanisms HIV Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAIDS Journal of Acquired Immune Deficiency Syndromes

Volume 72, Issue 4, pp. 400-407

DOI: 10.1097/qai.0000000000000983

Field-Weighted Citation Impact: 10.03